GSK
HealthcareGSK plc · Drug Manufacturers - General · $104B
GSK Price History
+55.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in GSK plc?
Based on GSK plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Unlock Full GSK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓Detailed 6-pillar UQS breakdown with exact scores
- ✓All 29 metrics with sector-calibrated comparisons
- ✓6 investor presets (Buffett, Munger, Lynch, Wood, Graham, Balanced)
- ✓Watchlist tracking with score alerts
- ✓AI-generated investment perspectives across 6 preset views
- ✓Score history chart with change notifications
Pro Analysis
GSK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Jul 25, 2026 | 59.4 | 82.9 | 59.0 | 28.1 | 42.9 | 79.1 | -0.3 |
| Jul 23, 2026 | 59.7 | 83.0 | 59.0 | 28.1 | 42.9 | 80.8 | 0.0 |
| Jul 22, 2026 | 59.7 | 83.1 | 59.0 | 28.1 | 42.9 | 81.1 | -0.1 |
| Jul 21, 2026 | 59.8 | 83.2 | 59.0 | 28.1 | 42.9 | 81.1 | +0.3 |
| Jul 18, 2026 | 59.5 | 82.9 | 59.0 | 28.0 | 42.9 | 79.6 | +0.3 |
| Jul 17, 2026 | 59.2 | 82.7 | 59.0 | 28.1 | 42.9 | 78.5 | -0.3 |
| Jul 15, 2026 | 59.5 | 82.9 | 59.0 | 28.1 | 42.9 | 79.6 | +0.2 |
| Jul 14, 2026 | 59.3 | 82.7 | 59.0 | 28.2 | 42.9 | 78.7 | +0.2 |
| Jul 13, 2026 | 59.1 | 82.6 | 59.0 | 28.3 | 42.9 | 77.5 | 0.0 |
| Jul 11, 2026 | 59.1 | 82.6 | 59.0 | 28.2 | 42.9 | 77.2 | 0.0 |
GSK — Pillar Breakdown
Quality
— 82.9/100 (25%)GSK plc demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 28.1/100 (20%)GSK plc faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 42.9/100 (15%)GSK plc has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 80.8/100 (15%)GSK plc appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 59/100 (25%)GSK plc has meaningful competitive advantages that should protect its market position. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GSK.
Score Composition
Financial Data
More Stock Analysis
How is the GSK UQS Score Calculated?
The UQS (Unified Quality Score) for GSK plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses GSK plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether GSK plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.